Remove Clinical Development Remove Drug Development Remove Science
article thumbnail

The rising impact of biomarkers in early clinical development

Drug Target Review

In a recent survey conducted by ICON, Plc, biomarker selection was identified by 35 percent of respondents as a top challenge among drug developers for phase I trials, second only to navigating regulatory compliance (- 38 percent). Biomarkers can play a crucial role throughout clinical development, especially in early phases.

article thumbnail

Revolution Medicines Secures $2B Funding from Royalty Pharma for RAS(ON) Cancer Drug Development

The Pharma Data

Through this transaction, Revolution Medicines maintains full ownership and executional control over its clinical programs and commercial strategy in the U.S. and internationally, providing the company with the flexibility to pursue its long-term vision of transforming care for patients with RAS-addicted cancers.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Drug development is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates. Highlighting data integration.

Drugs 65
article thumbnail

Why radiopharmaceuticals are gaining ground in the fight against cancer

Drug Target Review

Image credit: Crystal Eye Media / Shutterstock The role of SPICA and manufacturing capabilities Drug development in the radiopharmaceutical space is particularly resource intensive. He stresses the importance of recognising organisational strengths and weaknesses: “No single company is fully expert in all aspects of drug development.”

Therapies 100
article thumbnail

Leveraging AI Solutions for Clinical Trial Efficiencies

PPD

As a result, drug developers make better decisions more quickly (removing 50% of study timeline whitespace) to bring new therapies to market faster. Accelerate customer speed to market With a modern and integrated user experience, AI solutions put the right data and insights into the right hands in real time.

article thumbnail

AI in drug discovery: faster, smarter, better

Drug Target Review

Zylberberg has built an impressive career at the intersection of science, technology, and business. The future of AI in CGT AI holds tremendous potential to reshape drug discovery and development in CGT. Were developing user-friendly AI tools that dont require a PhD in data science to operate, she explains.

Drugs 90
article thumbnail

Inside AACR: DARPins take aim at hard-to-treat tumours

Drug Target Review

Amelie Croset, Senior Director of Alliances and Partnering at the therapeutics company Molecular Partners, spoke with Drug Target Review about the science behind the presentation posters, its therapeutic potential and what is next for the platform. ” From there, things moved fast. ” And what a year to make the switch. .

Science 52